Search the Newsreel

BELI of Djarum Group remains loss-making as shares fall 43% since IPO

Polibeli Group Ltd stock hits 52-week low at 5.21 USD

Polibeli Group Ltd (PLBL) stock has hit a new 52-week low of $5.21, marking a 61% drop from its high and a 51.12% decrease over the past year. InvestingPro analysis rates the company's financial health as "WEAK" and suggests the stock may be overvalued. …

Polibeli Group Ord Shs Class A (PLBL) Earnings Forecast: Future EPS & Revenue Growth Estimates

This article provides an earnings forecast for Polibeli Group Ord Shs Class A (PLBL), specifically focusing on future EPS and revenue growth estimates. It includes a snapshot of current stock performance, market capitalization, and a direct peer comparison. The content also mentions various financial …

Polibeli Group Ord Shs Class A (PLBL) Valuation: PE, PB & Fair Value Analysis

This article displays valuation information for Polibeli Group Ord Shs Class A (PLBL), including its current stock price, market capitalization, and a note on its P/E ratio which indicates a loss. It also provides navigation to other financial analysis tools, company overview, and discussion …

BLIV|BeLive Holdings|Price:2.110|Chg%:-0.070

This article provides a detailed financial overview of BeLive Holdings (BLIV), including real-time quotes, market trends, key figures, and technical indicators. It highlights the company's business as a provider of technology solutions for live commerce and shoppable short videos. The report also lists major …

Polibeli Group Ord Shs Class A (PLBL) Dividends & Stock Splits: Historical Payouts and Event Timeline

This article provides an overview of Polibeli Group Ord Shs Class A (PLBL) stock performance and its dividend history. It indicates that the company has distributed $0.00 in dividends over the past five years. The stock closed at $7.350 with a -2.58% change and …

BeLive Holdings (BLIV) Cash Flow

This article provides an analysis of BeLive Holdings' (BLIV) cash flow statements, including operating, investing, financing, and free cash flow. It details key financial figures such as a -2.84M operating cash flow in fiscal 2025 and -2.90M free cash flow in the latest quarter, …

Polibeli Group Ord Shs Class A (PLBL) Shareholder Structure: Major Shareholders & Institutional Holdings

The Polibeli Group Ord Shs Class A (PLBL) shareholder structure shows XINGYUN INTERNATIONAL Co Ltd as the dominant shareholder with 98.00% of shares. Institutional holdings data up to Q4 2026 indicates 40 institutions hold 3.39M shares, representing 2.93% of the company. The article details …

BeLive Holdings (BLIV) Valuation: PE, PB & Fair Value Analysis

This article provides a valuation analysis for BeLive Holdings (BLIV), presenting its current stock price, market capitalization, and P/E TTM ratio. It also highlights the stock's daily price movement, showing a positive change of 3.79%. The content acts as a brief snapshot of the …

Polibeli Group Ord Shs Class A (PLBL) Balance Sheet

This article provides a detailed balance sheet for Polibeli Group Ord Shs Class A (PLBL), including quarterly and annual financial data. It itemizes assets, liabilities, and shareholders' equity, and offers a Q&A section explaining key balance sheet metrics and financial categories. The data presented …

Polibeli Group Ord Shs Class A (PLBL) Cash Flow

This article provides an overview of Polibeli Group Ord Shs Class A (PLBL)'s Q1 FY2025 cash flow statement, including operating, investing, and financing cash flows. It details key financial figures such as a -140.41K operating cash flow and a -6.51M free cash flow, explaining …

Belite Bio Inc (BLTE) Valuation: PE, PB & Fair Value Analysis

This article provides a brief valuation analysis for Belite Bio Inc (BLTE), focusing on its P/E, P/B, and P/CF ratios. It states that relevant data for these metrics have not yet been disclosed by the company. The page also displays the current stock price, …

BeLive Holdings (BLIV) Shareholder Structure: Major Shareholders & Institutional Holdings

This article details the shareholder structure of BeLive Holdings (BLIV), outlining major shareholders and institutional holdings. It provides a breakdown of ownership by proportion for entities like FTAG Ventures Pte Ltd and individual investors, alongside historical institutional shareholding data and recent shareholder activity.

Belite Bio Inc (BLTE) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution

This article for Belite Bio Inc (BLTE) on TradingKey discusses the company's revenue breakdown. It states that relevant data regarding business segments, regional revenue, and profit contribution have not yet been disclosed by the company. The article provides current stock performance details like market …

PLBL|Polibeli Group Ord Shs Class A|Price:7.545|Chg%:-0.225

This article provides an overview of Polibeli Group Ord Shs Class A (PLBL) stock, including its current price of $7.545, a decrease of 2.90%. It highlights that no stock score is available due to insufficient data but explains how TradingKey generally calculates various scores …

BeLive Holdings Revenue Breakdown – NASDAQ:BLIV

This article provides a revenue breakdown for BeLive Holdings (NASDAQ:BLIV), highlighting that the largest contribution to its revenue came from the Asia & Oceania region. Last year, this region accounted for over $579K USD, though this was a decrease from $1.37M USD in the …

Belite Bio Inc (BLTE) Risk Assessment: Volatility, Financial Risk & Investment Risk

This article provides a risk assessment for Belite Bio Inc (BLTE), focusing on its volatility, financial risk, and overall investment risk. It details various metrics including Beta, VaR, Maximum Drawdown, Volatility, Sharpe Ratio, and Liquidity. The data indicates significant volatility and downside risk for …

TradingKey

This article provides an income statement overview for BeLive Holdings (BLIV) on the TradingKey platform. It details financial metrics for fiscal year 2025, including revenue, net income, and operating profit, and offers guidance on how to interpret these statements. The page also includes FAQs …

Price to sales forward of Belite Bio, Inc. ADR – FWB:D01

This article provides access to the "Price to sales forward" financial metric for Belite Bio, Inc. ADR (FWB:D01) on the Frankfurt Stock Exchange. It indicates that the market is closed with no current trades. The content primarily serves as a gateway to financial data …

Polibeli Group Ltd Revenue Breakdown – NASDAQ:PLBL

The article provides a revenue breakdown for Polibeli Group Ltd (NASDAQ:PLBL), highlighting that Japan was its top-contributing segment last year, generating $10.81 million USD, down from $16.10 million USD the previous year. This data is available through TradingView, which offers various financial tools and …

Polibeli Group Ltd (PLBL) Analyst insights, Price targets and Recommendations

The article provides a snapshot of Polibeli Group Ltd (PLBL), including its current stock price and performance. It lists various sections available on Yahoo Finance for the company, such as news, charts, historical data, and financial analysis, but the content itself is mainly a …

Belite Bio Inc (BLTE) Shareholder Structure: Major Shareholders & Institutional Holdings

This article details the shareholder structure of Belite Bio Inc (BLTE), identifying its major shareholders and institutional holdings. It provides breakdowns of shareholder types, institutional shareholding over recent quarters, and individual shareholder activity, highlighting key investors like Lin Bioscience International, Ltd. and Darwin Global …

Belite Bio Inc (BLTE) Earnings Forecast: Future EPS & Revenue Growth Estimates

This article provides an earnings forecast for Belite Bio Inc (BLTE), detailing analyst ratings, price targets, and historical and projected EPS. Based on 8 analysts' opinions, the stock has a "Buy" rating with an average target price of USD 210.50, representing a potential upside …

Belite Bio, Inc. ADR Revenue Breakdown – FWB:D01

This article focuses on the revenue breakdown for Belite Bio, Inc. ADR (D01) on the Frankfurt Stock Exchange. It indicates that the company's market is currently closed with no trades. The main content points to various financial data and tools available on TradingView for …

BeLive Holdings Announces Closing of Approximately $10,000,000 Initial Public Offering

BeLive Holdings, a Singapore-based provider of live commerce and shoppable short video solutions, announced the closing of its initial public offering. The company raised $9.8 million by offering 2,450,000 ordinary shares at $4.00 per share and will trade on Nasdaq under the ticker "BLIV." …

Belite Bio Conference Highlights Tinlarebant Data and New Hope for Retinal Diseases

A recent H.C. Wainwright conference highlighted advancements in treating inherited retinal diseases, particularly Stargardt disease and retinitis pigmentosa. Belite Bio presented positive data for its drug tinlarebant, showing a significant reduction in macular lesion growth for Stargardt disease, while Nanoscope Therapeutics showcased MCO-010 as …

Belite Bio (BLTE) Leerink’s Global Healthcare Conference 2025 Summary

This article summarizes Belite Bio's presentation at Leerink's Global Healthcare Conference 2025, focusing on their drug Tinlarebant for Stargardt disease and geographic atrophy. The summary details the disease background, drug mechanism, clinical trial designs (Phase II, DRAGON, DRAGON 2, and GA studies), and efficacy …

Belite Bio stock price target maintained at $200 by H.C. Wainwright

H.C. Wainwright has reiterated a Buy rating and a $200 price target for Belite Bio (NASDAQ:BLTE), citing positive secondary endpoint data from its Phase 3 DRAGON trial for tinlarebant in Stargardt disease type 1. The stock has seen a 170% return over the past …

Belite Bio, Inc (BLTE) Stock Analysis: A 37.73% Upside Potential in the Biotechnology Sector

Belite Bio, Inc (BLTE) is a clinical-stage biopharmaceutical company with a promising 37.73% upside potential, according to analyst ratings. The company is focused on developing therapies for Stargardt disease type 1 and geographic atrophy, with its lead product Tinlarebant (LBS-008) in phase 3 clinical …

Enterprise value to revenue forward of Polibeli Group Ltd – NASDAQ:PLBL

This article provides the enterprise value to revenue forward for Polibeli Group Ltd (NASDAQ:PLBL). It appears to be a financial data snippet from TradingView, focusing on key financial metrics for the company. The content primarily displays navigation and boilerplate information from the TradingView platform, …

Tinlarebant retinal marker stayed stable or fell ~2%; placebo rose 20%

Belite Bio reported additional positive secondary endpoint data from its Phase 3 DRAGON trial of tinlarebant for Stargardt disease type 1. The data, presented at ASRS 2026 Annual Meeting, showed that quantitative autofluorescence remained stable to slightly decreased in tinlarebant-treated subjects, while it increased …

BeLive Holdings (BLIV) CEO and Board Chair to step down; CFO named interim

BeLive Holdings announced that its CEO and Chairman, Kenneth Teck Chuan Tan, will step down, effective October 3, 2026, after serving since August 2023. The company clarified there was no disagreement regarding operations, policies, or practices. Abdul Latif Bin Zainals, currently CFO, will assume …

Belite Bio completes FDA filing for tinlarebant in Stargardt disease type 1

Belite Bio has completed its New Drug Application (NDA) filing with the FDA for tinlarebant, aiming to treat Stargardt disease type 1. This news brief, generated by AI, is for informational purposes only and references original content published by Belite Bio via GlobeNewswire.

Belite Bio Announces Oral Presentation at the ASRS Annual Meeting Featuring Additional Positive Secondary Endpoint Data from the Phase 3 Trial of Tinlarebant in Stargardt Disease Type 1

Belite Bio announced additional positive secondary endpoint data from its Phase 3 DRAGON trial of tinlarebant in Stargardt disease type 1 (STGD1), which demonstrated a marked divergence in quantitative autofluorescence (qAF) between treatment groups. Tinlarebant showed stable to slightly decreased qAF values, while placebo …

Polibeli Group Ltd (PLBL) latest press releases and corporate news

Polibeli Group Ltd (PLBL) has announced two recent non-binding Memorandums of Understanding (MOUs). One MOU aims to evaluate a potential AI Data Center opportunity in Indonesia, and another explores a 100 MW AI Computing Center Project in Thailand. The company's stock, PLBL, closed at …

BeLive Holdings CEO And Chairman Kenneth Tan Resigns, Effective October 3, 2026 - Filing

BeLive Holdings announced that CEO and Chairman Kenneth Tan will resign from his positions, effective October 3, 2026. This information was disclosed in a regulatory filing.